O4CP

O4CP is a French biotechnology company focused on the development of innovative small molecule therapies targeting G protein-coupled receptors (GPCRs) for the treatment of chronic inflammatory and fibrotic diseases. The company's lead program centers on GPR84 antagonists, which aim to modulate the immune response and reduce tissue damage in conditions such as inflammatory bowel disease (IBD) and nonalcoholic steatohepatitis (NASH). By leveraging its expertise in GPCR pharmacology, O4CP seeks to provide next-generation oral treatments that offer improved efficacy and safety profiles compared to current standards of care. The company operates primarily in the pre-clinical stage, advancing its pipeline toward regulatory filings and clinical proof-of-concept.